Press Releases

EditForce, Inc. has entered into a License Agreement  with Mitsubishi Tanabe Pharma Corporation to research, develop and commercialize potential gene therapy products for a disease-specific targeting in the CNS field by using EditForce's proprietary PPR protein platform technology. EditForce, Inc. logo:  https://kyodonewsprwire.jp/prwfile/release/M107232/202206242954/_prw_PI1fl_09s1955H.webp  Through this alliance, MTPC and EditForce aim to create potent

 Altasciences is expanding its formulation, manufacturing and analytical services facilities in Philadelphia, Philadelphiacontinue. The integrated contract research, development and manufacturing (CRO/CDMO) organization that provides pharmaceutical and biotechnology companies with a proven, flexible approach to preclinical and clinical pharmacology studies is building for Alladapt Immunotherapeutics, Inc. (“Alladapt”) – a privately held biopharmaceutical Clinical-stage

TME Pharma N.V., a biotechnology company focused on developing novel therapies for treatment of cancer by targeting the tumor microenvironment (TME), announced today it has officially changed its corporate name from “NOXXON Pharma N.V.” to “TME Pharma N.V.” and the ticker symbol for the company’s common stock on the Euronext Growth Paris will change from “ALNOX” to “ALTME”. Trading under the new name and ticker symbol will begin at the mar

Clarify Health, a leading cloud analytics and value-based payments platform company, announced the launch of Clarify Access, real-world insights software that helps life sciences companies strengthen market access strategies and improve reporting efficiency through the delivery of on-demand reporting and payer insights. With Clarify Access, pharma teams can more rapidly adjust market access strategies, instantly pinpoint formulary advantages and weaknesses to better enable their field force a

BeiGene , a global oncology biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide, today announced that the U.S. Food and Drug Administration (FDA) has deferred action on the Biologics License Application (BLA) for tislelizumab as a second-line (2L) treatment for patients with unresectable or metastatic esophageal squamous cell carcinoma (ESCC). The FDA has been unable to conduct required inspections in

Aculys Pharma, Inc.  empresa centrada en el desarrollo y la comercialización de nuevos medicamentos innovadores en los campos de la neurología y la psiquiatría, ha firmado un contrato con SUSMED, Inc., una empresa que promueve la medicina digital (sede de "SUSMED": Chuo-ku, Tokio; CEO: Taro Ueno), para llevar a cabo el primer ensayo clínico del mundo1 patrocinado por una empresa que utiliza la tecnología de cadena de bloques (blockchain).

FSD Pharma Inc.  a life sciences holding company dedicated to building a portfolio of assets and biotech solutions, announced today that is wholly owned subsidiary, Lucid Psycheceuticals Inc. (“Lucid”), filed a provisional patent application on novel formulations of palmitoylethanolamide (PEA). The new patent application is based on the results of completed preclinical animal toxicology studies and phase 1 clinical trial using FSD201 (ultramicronized PEA), sponsored by FSD Ph

Saphetor, a global precision medicine company and the creator of VarSome, The Human Genomics Community and variant interpretation platform, announced today a partnership with) PTC Therapeutics International Limited. The open genomics community, VarSome.com, brings together a vast global network of clinical and research genetic laboratories leveraging its industry-leading genomic annotation tools and data. The collaboration will be centered around supporting awareness of clinical programs in r

Akanda Corp.  and Tetra Bio-Pharma , today jointly announced that Akanda will supply Tetra with pharmaceutical grade cannabis flower in a microdose cap form, for use in a Storz & Bickel Mighty Medic Vaporizer for global commercialization of Tetra’s QIXLEEFTM and related products. In addition, Akanda will act as a Contract Development and Manufacturing Organization (CDMO) for Tetra’s clinical drug and commercial supply programs. With this project, Akanda becomes a CDMO in

Aculys Pharma, Inc.  a company focused on the development and commercialization of new innovative drugs in the fields of neurology and psychiatry, has entered into a contract with SUSMED, Inc., a company that promotes digital medicine, ("SUSMED" Headquarters: Chuo-ku, Tokyo, CEO: Taro Ueno) to conduct the world's first1 corporate-sponsored clinical trial using blockchain technology. The clinical trial utilizing this blockchain technology, provided by SUSMED, will be conduct